Given that there was no significant difference between active and non-active comparison conditions, all comparison conditions were included in moderator analyses. Table 3 presents the results of moderator analyses across all three outcome types. Although there was a non-significant trend for larger treatment effects in CMI trials relative to SSRI trials, there were no significant differences in treatment efficacy (g=0.73 vs. 0.45) or treatment response (RR=3.56 vs. 1.68). There was a small negative association between methodological quality and ES for treatment response (p=0.04), with trials that had greater methodological rigor exhibiting smaller ES. There were no other significant moderators of treatment efficacy, treatment response, or symptom/diagnostic remission among SRI trials.
